• Correlation of sensitivity, specificity, positive predictive value, and negative predictive value of fludeoxyglucose F 18 positron emission tomography scan with clinical outcome [ Designated as safety issue: No ]
  
• Progression-free survival [ Designated as safety issue: No ]
  

OBJECTIVES:

• To determine if a fludeoxyglucose F 18 positron emission tomography scan, performed as early as day 30 after high-dose chemotherapy and autologous stem cell transplantation, may be useful in identifying patients with non-Hodgkin lymphoma who may benefit from early interventions, including reduced intensity stem cell transplantation or additional therapy, to preempt disease relapse and improve overall survival.

OUTLINE: Conventional imaging, biopsy, and clinical examination findings are reviewed to determine patient clinical outcome (e.g., complete response, disease progression/relapse, or death related to the primary disease).